Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

Journal of Neurology

Volumn 255, Issue 4, 2008, Pages 480-487

  Polman, C ^a   Kappos, L ^b   Freedman, M S ^c   Edan, G ^d   Hartung, H P ^e   Miller, D H ^f   Montalban X ^g   Barkhof, F ^a   Selmaj, K ^h   Uitdehaag, B M J ^a   Dahms, S ⁱ   Bauer, L ⁱ   Pohl, C ⁱ   Sandbrink, R ⁱ  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF OTTAWA   (Canada)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h MEDICAL UNIVERSITY OF LODZ   (Poland)

ⁱ BAYER PHARMA AG   (Germany)

Author keywords

CIS; MRI; Multiple sclerosis

Indexed keywords

GADOLINIUM PENTETATE; INTERFERON BETA SERINE; PLACEBO; STEROID;

ADULT; AGE DISTRIBUTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYMPTOM; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EARLY DIAGNOSIS; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PLACEBO EFFECT; PLACEBOS; RISK FACTORS; STEROIDS; TREATMENT OUTCOME;

EID: 42549111379     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-0733-2     Document Type: Article

References (21)

1. Barkhof F, Filippi M, Miller DH, et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (Pt 11):2059-2069
2. Barkhof F, Rocca M, Francis G, et al. (2003) Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 53:718-724
3. Beck RW, Chandler DL, Cole SR, et al. (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481-90
4. Beck RW, Cleary PA, Anderson MM Jr, et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581-588
5. CHAMPS Study Group (2002) Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Mult Scler 8:405-409
6. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782
7. European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
8. Held U, Heigenhauser L, Shang C, Kappos L, Polman C (2005) Predictors of relapse rate in MS clinical trials. Neurology 65:1769-1773
9. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43:655-661
10. Jacobs LD, Beck RW, Simon JH, et al. (2000) Intramuscular interferon beta- 1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898-904
11. Kappos L, Polman CH, Freedman MS, et al. (2005) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242-1249
12. Korteweg T, Tintore M, Uitdehaag B, et al. (2006) MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 5:221-227
13. Li DK, Held U, Petkau J, et al. (2006) MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66:1384-1389
14. Miller DH, Molyneux PD, Barker GJ, et al. (1999) Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, doubleblind, placebo-controlled trial. Ann Neurol 46:850-859
15. O'Connor P (2003) The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 25:2865-2874
16. Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662-667
17. Poser CM, Paty DW, Scheinberg L, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
18. Soderstrom M, Ya-Ping J, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50:708-714
19. Tintore M, Rovira A, Brieva L, et al. (2001) Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 7:359-363
20. Tintore M, Rovira A, Rio J, et al. (2005) Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 57:210-215
21. Uitdehaag BM, Kappos L, Bauer L, et al. (2005) Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler 11:227-231